Semeraro C, Dorigotti L, Banfi S, Carpi C, Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug, in J. Cardiovasc. Pharmacol., vol. 3, n. 3, 1981, pp. 455–67, PMID6168827.
Simonotti L, Zanol M, Parravicini F, Pifferi G, Studies on the metabolism of cadralazine in rat, in Eur J Drug Metab Pharmacokinet, vol. 7, n. 1, 1982, pp. 39–45, PMID7067722.
Bonardi G, Rossi E, Pellegatti M, [14C]cadralazine: absorption, distribution and excretion in rat and dog, in Eur J Drug Metab Pharmacokinet, vol. 8, n. 1, 1983, pp. 25–33, PMID6861793.
Lecaillon JB, Dubois JP, Darragon T, et al., Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients, in Ther Drug Monit, vol. 13, n. 2, marzo 1991, pp. 103–8, PMID2053115.
Hauffe SA, Dubois JP, Imhof PR, Human pharmacokinetics of cadralazine: a new vasodilator, in Eur J Drug Metab Pharmacokinet, vol. 10, n. 3, 1985, pp. 217–23, PMID4085523.
Leonetti G, Parini J, Visconti M, Gradnik R, Pharmacokinetics of cadralazine in hypertensive patients, in Eur J Drug Metab Pharmacokinet, vol. 13, n. 4, 1988, pp. 295–300, PMID3243325.
Marichal JF, Brunel P, Lecaillon JB, et al., Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily, in Eur J Drug Metab Pharmacokinet, vol. 17, n. 3, 1992, pp. 213–20, PMID1490491.
Catalano M, Parini J, Libretti A, Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients, in Eur. J. Clin. Pharmacol., vol. 24, n. 2, 1983, pp. 157–61, PMID6840161.
Catalano M, Parini J, Romano M, Libretti A, Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension, in Eur. J. Clin. Pharmacol., vol. 28, n. 2, 1985, pp. 135–8, PMID3886402.
McTavish D, Young RA, Clissold SP, Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension, in Drugs, vol. 40, n. 4, ottobre 1990, pp. 543–60, PMID2083513.
Salvadeo A, Villa G, Segagni S, et al., Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension, in Arzneimittelforschung, vol. 35, n. 3, 1985, pp. 623–5, PMID2859865.
Lavezzaro GC, Gastaldo D, Noussan P, Bensoni M, Parini J, Angelino PF, [Effects of cadralazine (ISF 2469) on water-sodium balance and on essential arterial hypertension], in Minerva Cardioangiol, vol. 29, n. 10, ottobre 1981, pp. 527–34, PMID7322375.
Caponnetto S, Valvo E, Mocarelli P, Alberti D, Savonitto S, Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group, in Eur. J. Clin. Pharmacol., vol. 40, n. 5, 1991, pp. 461–5, PMID1679390.
Andersson OK, Cadralazine did not produce the SLE-syndrome when hydralazine did, in Eur. J. Clin. Pharmacol., vol. 31, n. 6, 1987, p. 741, PMID3556384.
Mulder H, Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine, in Eur. J. Clin. Pharmacol., vol. 38, n. 3, 1990, p. 303, PMID2340851.
